MEDICUS PHARMA LTD (MDCX) Fundamental Analysis & Valuation

NASDAQ:MDCX • CA58471K2020

Current stock price

0.3513 USD
+0.05 (+16.98%)
At close:
0.3265 USD
-0.02 (-7.06%)
After Hours:

This MDCX fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

0

1. MDCX Profitability Analysis

1.1 Basic Checks

  • MDCX had negative earnings in the past year.
  • MDCX had a negative operating cash flow in the past year.
  • In the past 5 years MDCX always reported negative net income.
  • MDCX had a negative operating cash flow in each of the past 5 years.
MDCX Yearly Net Income VS EBIT VS OCF VS FCFMDCX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -10M -20M -30M -40M

1.2 Ratios

  • MDCX's Return On Assets of -835.67% is on the low side compared to the rest of the industry. MDCX is outperformed by 95.16% of its industry peers.
  • MDCX has a worse Return On Equity (-2201.60%) than 83.14% of its industry peers.
Industry RankSector Rank
ROA -835.67%
ROE -2201.6%
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
MDCX Yearly ROA, ROE, ROICMDCX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -5K -10K -15K -20K

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for MDCX so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
MDCX Yearly Profit, Operating, Gross MarginsMDCX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

5

2. MDCX Health Analysis

2.1 Basic Checks

  • MDCX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
MDCX Yearly Shares OutstandingMDCX Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M 10M
MDCX Yearly Total Debt VS Total AssetsMDCX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 1M 2M 3M 4M 5M

2.2 Solvency

  • Based on the Altman-Z score of -20.98, we must say that MDCX is in the distress zone and has some risk of bankruptcy.
  • MDCX has a Altman-Z score of -20.98. This is amonst the worse of the industry: MDCX underperforms 84.30% of its industry peers.
  • MDCX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -20.98
ROIC/WACCN/A
WACCN/A
MDCX Yearly LT Debt VS Equity VS FCFMDCX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -5M -10M -15M -20M

2.3 Liquidity

  • MDCX has a Current Ratio of 1.53. This is a normal value and indicates that MDCX is financially healthy and should not expect problems in meeting its short term obligations.
  • MDCX has a worse Current ratio (1.53) than 82.36% of its industry peers.
  • A Quick Ratio of 1.53 indicates that MDCX should not have too much problems paying its short term obligations.
  • MDCX has a Quick ratio of 1.53. This is amonst the worse of the industry: MDCX underperforms 80.62% of its industry peers.
Industry RankSector Rank
Current Ratio 1.53
Quick Ratio 1.53
MDCX Yearly Current Assets VS Current LiabilitesMDCX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M 10M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

1

3. MDCX Growth Analysis

3.1 Past

  • MDCX shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -15.65%.
EPS 1Y (TTM)-15.65%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-361.11%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • The Earnings Per Share is expected to grow by 23.67% on average over the next years. This is a very strong growth
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y72.3%
EPS Next 2Y34.98%
EPS Next 3Y24.17%
EPS Next 5Y23.67%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
MDCX Yearly Revenue VS EstimatesMDCX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2028 2029 2030 2031 2032 2033 200M 400M 600M
MDCX Yearly EPS VS EstimatesMDCX Yearly EPS VS EstimatesYearly EPS VS Estimates 2023 2024 2025 2026 2027 2028 2029 2030 0 1 -1 2 -2

More info and screens

Find the best growth stocksShow best growing peers

1

4. MDCX Valuation Analysis

4.1 Price/Earnings Ratio

  • MDCX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for MDCX. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
MDCX Price Earnings VS Forward Price EarningsMDCX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
MDCX Per share dataMDCX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.5 -1 -1.5 -2

4.3 Compensation for Growth

  • MDCX's earnings are expected to grow with 24.17% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y34.98%
EPS Next 3Y24.17%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. MDCX Dividend Analysis

5.1 Amount

  • No dividends for MDCX!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

MDCX Fundamentals: All Metrics, Ratios and Statistics

MEDICUS PHARMA LTD

NASDAQ:MDCX (4/17/2026, 8:00:00 PM)

After market: 0.3265 -0.02 (-7.06%)

0.3513

+0.05 (+16.98%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-25
Earnings (Next)05-11
Inst Owners10.02%
Inst Owner Change0%
Ins Owners6.18%
Ins Owner Change0%
Market Cap13.83M
Revenue(TTM)N/A
Net Income(TTM)-47.28M
Analysts82.22
Price Target7.14 (1932.45%)
Short Float %6.21%
Short Ratio0.42
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-275.22%
Min EPS beat(2)-430.7%
Max EPS beat(2)-119.74%
EPS beat(4)0
Avg EPS beat(4)-171.84%
Min EPS beat(4)-430.7%
Max EPS beat(4)-60.43%
EPS beat(8)2
Avg EPS beat(8)-118.99%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-64.41%
PT rev (3m)-68.66%
EPS NQ rev (1m)-29.41%
EPS NQ rev (3m)48.24%
EPS NY rev (1m)19.57%
EPS NY rev (3m)27.59%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 6.44
P/tB 6.44
EV/EBITDA N/A
EPS(TTM)-2.32
EYN/A
EPS(NY)-0.64
Fwd EYN/A
FCF(TTM)-0.58
FCFYN/A
OCF(TTM)-0.58
OCFYN/A
SpS0
BVpS0.05
TBVpS0.05
PEG (NY)N/A
PEG (5Y)N/A
Graham Number0 (-100%)
Profitability
Industry RankSector Rank
ROA -835.67%
ROE -2201.6%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.53
Quick Ratio 1.53
Altman-Z -20.98
F-Score6
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-15.65%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-361.11%
EPS Next Y72.3%
EPS Next 2Y34.98%
EPS Next 3Y24.17%
EPS Next 5Y23.67%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-129.34%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-122.27%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-122.27%
OCF growth 3YN/A
OCF growth 5YN/A

MEDICUS PHARMA LTD / MDCX Fundamental Analysis FAQ

Can you provide the ChartMill fundamental rating for MEDICUS PHARMA LTD?

ChartMill assigns a fundamental rating of 2 / 10 to MDCX.


What is the valuation status for MDCX stock?

ChartMill assigns a valuation rating of 1 / 10 to MEDICUS PHARMA LTD (MDCX). This can be considered as Overvalued.


How profitable is MEDICUS PHARMA LTD (MDCX) stock?

MEDICUS PHARMA LTD (MDCX) has a profitability rating of 0 / 10.


What is the earnings growth outlook for MEDICUS PHARMA LTD?

The Earnings per Share (EPS) of MEDICUS PHARMA LTD (MDCX) is expected to grow by 72.3% in the next year.